ABSTRACT

Introduction: Timely initiation of treatment is crucial for program management in countries with a high burden of multidrugresistant tuberculosis (MDR-TB). The delay in the initiation of the treatment allows the transmission in the community and the appearance of TB-MDR cases. Material and methods: Retrospective review of the files of the Tuberculosis Clinic of the Tijuana General Hospital, including all cases with a diagnosis of tuberculosis with rifampicin resistance (RRTB) or MDR-TB, during the period between 2006-2019. The interval (in days) between the regimen prescription and the start of treatment was determined. Results: 52 patients were included. The delay in the initiation of treatment after having recommended a treatment regimen for TB-RR /MDR was 115.6 ± 109.2 days (3.8 months) with a median of 97.5 days. The delay in patients who were cured was 113.4 days versus 155.0 days for patients who died (p = 0.83). Conclusions: The time interval between prescription of treatment of an RR/MDR-TB case and the start of treatment (115 days) is unacceptably long. The network for MDR-TB care would be strengthened with the decentralization of stocks of second-line anti-tuberculosis drugs.

KEYWORDS

Multidrug resistance, delay, treatment, tuberculosis.

REFERENCES

1. Htun YM, Khaing TMM, Yin Y, et al. Delay in diagnosis and treatment among adult multidrug resistant tuberculosis patients in Yangon Regional Tuberculosis Center, Myanmar: a cross-sectional study. BMC Health Serv Res 2018;18(1):878. doi: 10.1186/s12913-018-3715-4.

2. Harris RC, Grandjean L, Martin LJ, et al. The effect of early versus late treatment initiation after diagnosis on the outcomes of patients treated for multidrug-resistant tuberculosis: a systematic review. BMC Infect Dis 2016;16(1):193. doi:10.1186/s12879-016-1524-0.

3. Madala P, Jonnalagadda RK, Sastry TVSN, Samyukta R, Hanumanth N, Raju CN. A study to identify the factors responsible for the delay in treatment initiation of MDR–TB cases registered under RNTCP in a district of South India. Int J Scient Res 2016;5(9):397-401. doi : 10.36106/ijsr.

4. Pan American Health Organization. Tuberculosis in the Americas, 2018. Washington, DC: PAHO, 2018 Document Number: PAHO/ CDE/18-036.

5. Htun YM, Khaing TMM, Aung NM, et al. Delay in treatment initiation and treatment outcomes among adult patients with multidrug-resistant tuberculosis at Yangon Regional Tuberculosis Centre, Myanmar: A retrospective study. PLoS One 2018;13(12): e0209932. doi: 10.1371/ journal.pone.0209932.

6. Htun YM, Khaing TMM, Yin Y, et al. Delay in diagnosis and treatment among adult multidrug resistant tuberculosis patients in Yangon Regional Tuberculosis Center, Myanmar: a cross-sectional study. BMC Health Serv Res 2018;18(1):878. doi: 10.1186/s12913-018-3715-4.

7. Zhang X, Yin J, Li H, et al. Diagnostic and treatment delays of multidrug-resistant tuberculosis before initiating treatment: a crosssectional study. Trop Med Int Health 2015;20(11):1431-1437. doi: 10.1111/tmi.12566

8. Rifat M, Hall J, Oldmeadow C, Husain A, Milton AH. Health system delay in treatment of multidrug resistant tuberculosis patients in Bangladesh. BMC Infect Dis 2015;15:526. doi: 10.1186/s12879-015-1253-9.

9. Okethwangu D, Birungi D, Biribawa C, et al. Multidrug-resistant tuberculosis outbreak associated with poor treatment adherence and delayed treatment: Arua District, Uganda, 2013–2017. BMC Infectious Diseases 2019;19(1):387. doi: 10.1186/s12879-019-4014-3.

10. Rifat M, Rusen ID, Islam MA, et al. Why are tuberculosis patients not treated earlier? A study of informal health practitioners in Bangladesh. Int J Tuberc Lung Dis 2011;15(5):647–651. doi: 10.5588/ijtld.10.0205.

11. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. World Health Organization 2013. ISBN: 978 92 4 150633 5.